Cyclacel Pharma (CYCC) Misses Q2 EPS by 4c

Cyclacel Pharma (NASDAQ: CYCC) reported Q2 EPS of ($0.16), $0.04 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Cerebras Q1 EPS miss sends shares down 9% after-hours